Spironolactone Tablet, Film Coated
Product Images NDC 63187-841

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 63187-841). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spironolactone Structure (01)

Chemical structure diagram of spironolactone, the active ingredient in Spironolactone tablets. The diagram depicts the molecular arrangement and bonding of the compound.*

FDA Label Image

63187-841-03 (25mg)

Label for Spironolactone 25 mg film-coated tablets by Proficient Rx LP. The label states each tablet contains 25 mg of spironolactone USP. Tablets are described as brown, round, biconvex, with 'TL 216' debossed on one side and plain on the other. Manufactured by Jubilant Generics Limited in India. Storage instructions indicate 20°-25°C (68°-77°F). The label includes NDC 63187-841-03 and notes the medication is RX only.*

FDA Label Image

Figure 2 (Fig 2)

A line graph depicting probability over time in months (0 to 48) for two groups: Spironolactone (n=822) and Placebo (n=841). The Spironolactone group shows a higher probability throughout the period compared to Placebo. The graph includes a log-rank p-value of less than 0.001, indicating statistically significant differences between the groups.*

FDA Label Image

Figure 3 (Fig 3)

A forest plot comparing hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups including age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The x-axis ranges from 0.2 to 1.4, indicating relative benefit of spironolactone versus placebo across subgroups, with subgroup sample sizes listed on the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.